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Abstract 
BACKGROUND AND AIM: Our aim was to assess the clinical efficacy of ginger capsule (Zintoma herbal capsule) in the 
relief of symptoms in patients with post-radiotherapy xerostomia. 
METHODS: This study was a randomized double-blind, parallel clinical trial of ginger usage in patients with  
post-radiotherapy xerostomia. Sixty-one subjects were selected from patients with xerostomia of Imam Khomeini 
Cancer Institute, Tehran, Iran. Subject-based dry mouth scores derived from 100 mm visual analogue scales (VAS) 
were recorded at baseline. Patients also completed a questionnaire on the first visit regarding the symptoms of 
xerostomia. The patients received ginger capsule (30 persons) or placebo (31 persons) three times daily over a 2-weeks 
period. At the end of day 14, dry mouth scores derived from VAS were recorded again and patients responded to the 
additional variables regarding dry mouth symptoms and quality of life issues. P < 0.05 was considered significant. Data 
were analyzed using SPSS. 
RESULTS: The mean treatment effect on day 14 was 33.7 ± 20.9 mm in the ginger group and 23.6 ± 17.3 mm in the 
placebo group. The analysis indicated marginally significant improvement of xerostomia with ginger prescription  
(P = 0.057). At the end of intervention there was no significant difference between the two groups regarding 
improvement of quality of life or dry mouth symptoms. 
CONCLUSION: It seems that ginger could be helpful in the treatment of xerostomia. Since ginger is considered a safe 
herbal medicine with only few and insignificant adverse/side effects further studies in larger group of patients are 
recommended to provide the effect of ginger on different complaints of xerostomia. 
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aliva is the production of major and 
minor salivary glands dispersed in 
the oral cavity. The subjective report 
of oral dryness is termed xerostomia.1 
Several factors can cause xerostomia, but 
radiation therapy is one of the main causes. 
Radiation therapy of the head and neck 
region is used for treatment of primary and 
recurrent tumors in the upper aerodigestive 
tract and squamous cell carcinoma (SCC) of 
oral cavity and sinuses, salivary gland 
tumors and nasopharynx carcinoma.2 
Radiotherapy is an effective treatment for 
head and neck cancer, but because traditional 
radiotherapy treatment fields frequently 
include the major salivary glands, xerostomia 
is a common late toxic effect of radiation 
therapy in patients with head and neck 
S 
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cancers.2-4 It has been proved that radiation 
exposure has its own side effects such as 
disordering the salivary function, microbial 
infections, tastelessness and 
osteoradionecrosis of the jaw.5 
Treatment of salivary hypofunction and 
xerostomia is primarily palliative and can be 
accomplished by multiple approaches6 such as 
chewing gum,7 sugar free lozenges,8,9 salivary 
substitutes,10 Biotène products, Oral balance 
products,11,12 and toothpastes.13 Amifostine 
has been approved by the Food and Drug 
Administration (FDA) to relief the incidence 
and severity of radiation-induced xerostomia, 
but it requires parenteral administration, has 
potential side effects, and is not universally 
available.14 Electro- stimulation of tongue and 
palate, hyperbaric oxygen therapy and herbal 
medications are used by researchers to 
improve xerostomia.13,15 
It is important to have a wide variety of 
products that can help modify the xerostomia 
symptoms. These products should be 
convenient to use, safe, with minimal side 
effects, and tested for safety and efficacy in 
controlled clinical trials.7 The superior trait of 
saliva is its oral immunologic protection, 
therefore can never be replaced by any other 
synthetic substitute.16  
Nowadays, there are various successful 
herbal drugs in clinical trials for alleviating 
xerostomia, Bakumondo-to, LongoVital, and 
linseed extract Salinum are examples of these 
drugs.15 
Chamani et al. showed that salivation after 
injection of ginger extract was significantly 
higher than that of other herbal extracts and 
the negative control group in rats  
(P < 0.010).13 According to some research on 
herbal drugs, ginger has excellent 
chronological effect on post-synaptic M3 
receptors.13,17 Extracts and fractions of ginger 
(Zingiber officinale) have been shown to 
protect against chemically-induced tissue 
damage. The radioprotective effect of ginger 
extract has also been confirmed.18-23 Ginger is 
not only known as a safe herbal medicine but 
also as an anti-cancer, anti-clotting, and  
anti-inflammatory agent that has analgesic 
activities.24  
In this study, we evaluated the effect of 
ginger on increasing salivation and 
improvement of quality of life and dry mouth 
symptoms in patients with post-radiotherapy 
xerostomia. 
Methods 
This study was a randomized double-blind, 
parallel clinical trial of ginger usage in 
patients with post-radiotherapy xerostomia. 
This proposal had been evaluated by the 
Ethics Committee of Kerman University of 
Medical Sciences, Kerman, Iran  
(code K/87/103). The participants read and 
signed an official consent form. Sixty-one 
subjects were selected from patients with 
xerostomia from the Imam Khomeini Cancer 
Institute, Tehran, Iran. Registration ID of 
IRCT was IRCT138807012227N2. 
In this research, the patients were minimum 
18 years old with a history of radiotherapy 
treatment for neck cancer who had major and 
minor salivary glands disorders and 
experienced symptoms such as dry month 
when taking foods orally. 
Exclusion criteria included any treatment for 
cancer in the last three months, patients who 
had not received the determined radiotherapy 
course completely, those who were pregnant, 
smokers, diabetics, those with recurrences of 
cancer or terminal cancer, Sjogren's syndrome, 
cancer of the salivary glands and other causes 
of xerostomia and those taking anticoagulant 
medication or nifedipine.25 
A pharmacognosist prepared drug 
packages in the same type with two different 
codes, A and B (patients and examiner were 
blinded to the packages’ ingredients), which 
consisted of starch capsule and Zintoma 
herbal capsule. Participants were randomly 
allocated by random digit numbering in two 
groups, received the package one by one 
until the sample size was completed. Patients 
of the experimental group (30 persons) were 
given the ginger capsule (Goldaru Company, 
Zintoma herbal capsule, Iran) three times 
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daily and patients of the control group  
(31 persons) received placebo three times 
daily over a 2-week period. Starch was used 
as placebo (Figure 1).  
Participants who signed the consent form 
were obligated not to use any other products 
or medicine for treatment of dry mouth, but 
were permitted to use frequent small sips of 
water or any other mouth care products for 
the relief of dry mouth as needed (e.g. topical 
analgesics, topical antiseptics, and antifungal 
treatments). 
To determine the presence of xerostomia 
in the study population, each patient was 
evaluated using the Fox questionnaire.26 In 
this way the patients were enrolled by their 
scores derived from 100 mm visual analogue 
scales (VAS) registered on day 0 and 14 of a 
2-weeks period. We categorized the patients 
into two groups according to their  
pre-intervention (baseline) VAS score: a. 
patients with significant xerostomia (x > 63.3 
mm) and b. patients with non-significant 
xerostomia (x < 63.3 mm). 
The patients received ginger capsule or 
placebo three times daily over a 2-weeks 
period. At the end of day 14, dry mouth 
scores derived from VAS were recorded 
again. The mean dry mouth VAS score on 
day 14 was considered as mean treatment 
effect in each group.25  
Patients also completed a questionnaire 
including continuous variables on the first 
visit regarding the symptoms of xerostomia 
such as speech, chewing and swallowing 
difficulties, bad taste and burning sensation. 
At the end of day 14, patients responded to 
the additional dichotomous variables 
regarding dry mouth symptoms and quality 
of life issues (Table 1). 
The Student’s t-test and chi-square test 
were used to compare initial group 
differences for continuous and categorical 
dates, respectively. To compare the 
xerostomia score, two-way analysis of 
variance (ANOVA) was used27 with  
 
 
Figure 1. Flow diagram of the study 
Assessed for eligibility (n = 70) 
Excluded (n = 1) 
Not meeting inclusion criteria (n = 0) 
Declined to participate (n = 1) 
Other reasons (n = 0) 
Analysed (n = 30) 
Lost to follow-up (living in far city and didn’t come back 
to institute for follow up) (n = 3) 
Allocated to intervention (n = 33) ginger group 
Received allocated intervention (n = 33) 
Did not receive allocated intervention (give reasons) (n = 0) 
Lost to follow-up (living in far city and did not come 
back to institute for follow-up) (n = 5) 
Allocated to intervention (n = 36) placebo group 
Received allocated intervention (n = 36) 
Did not receive allocated intervention (give reasons) (n = 0) 
Analysed (n = 31) 
Excluded from analysis (give 
Digit numbering allocation 
Analysis 
2-weeks follow-up 
Randomized (n = 69) 
The Head and neck cancer patients 
of Imam Khomeini Institute 
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Table 1. Patient questionnaire completed on day 0 and day 14* 
How dry is your mouth? (0 = not dry at all, 100 = worst imaginable dryness) 
Do you have difficulty chewing because of your dry mouth? (0 = no difficulties at all, 100 = very severe difficulties 
with chewing) 
Do you have difficulty swallowing because of your dry mouth? (0 = no difficulties at all, 100 = very severe 
difficulties swallowing) 
Is speech difficult because of your dry mouth? (0 = no difficulties at all, 100 = very severe difficulties with speech) 
Is taste affected by your dry mouth? (0 = not affected at all, 100 = very severe alteration of taste) 
Do you have a burning sensation in your mouth? (0 = no burning at all, 100 = very severe burning mouth) 
Did the drug make your dry mouth better? Yes/No 
Was the drug most useful in the night? Yes/No 
Did the drug stop you waking in the night? Yes/No 
Did the drug improve your sensation of taste? Yes/No 
If you wear denture, did the drug help with the retention of the denture? Yes/No 
Did you meet people more than you used to? Yes/No 
Did you speak to people more than you used to? Yes/No 
Did you get out of the house more than you used to? Yes/No 
Did the drug make chewing easier? Yes/No 
Did the drug make swallowing easier? Yes/No 
Did the drug make talking easier? Yes/No 
If you have a burning mouth, did the product improve the burning sensation? Yes/No 
Did the drug make your dry mouth better? (0 = not dry at all, 100 = worst imaginable dryness) 
*Questions 1-6 were asked on day 0, and questions 7-18 were mentioned on day 14 
 
treatment as one factor and the category of 
baseline xerostomia severity as the other. 
P < 0.05 was considered significant. Data 
were analyzed using SPSS software (version 
17, SPSS Inc., Chicago, IL, USA). 
Results 
Sixty-one patients participated in this study. 
After breaking the prescribed drug code, it 
was determined that 30 patients used ginger 
(Zintoma herbal capsule) and 31 patients 
used the placebo. 
The patients in both groups were compared 
together in different characteristics, such as 
age, sex and elapsed mean time after last 
radiotherapy. There was no significant 
difference between them (Table 2). 
Because exact categorization between the 
two groups for radiotherapy dose, the site 
and type of cancer was not possible, there 
was no estimation for type and site of cancer 
between both groups. 
Using the VAS patients were questioned 
about xerostomia before ginger or placebo 
prescription. The mean treatment effect on day 
14 (considering the categorization of patients in 
two groups with significant and non-significant 
xerostomia) was 33.7 ± 20.9 mm VAS score in 
the ginger group and 23.6 ± 17.3 mm VAS score 
in the placebo group (Figure 2). 
The two-way ANOVA test indicated 
marginally significant improvement of 
xerostomia with ginger prescription (P = 0.057). 
Meanwhile, there was no interaction between 
the ginger group and significant xerostomia 
(P = 0.930). 
 
Table 2. Comparison of baseline characteristics between the two groups 
P Placebo Ginger Characteristic 
   Sex 
0.711 24 (77.4) 22 (73.3) Male [n (%)] 
7 (22.6) 8 (26.7) Female [n (%)] 
0.506 54.4 ± 15.6 51.5 ± 18.4 Age (year) (mean ± SD) 
0.915 24.1 ± 57.3 25.3 ± 24.4 Time elapsed after last radiotherapy (month) (mean ± SD) 
   Systemic disease [n (%)] 
0.525 9 (29.0) 11 (36.7) Yes  
22 (71.0) 19 (63.3) No 
SD: Standard deviation 
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Table 3. Comparison of dry mouth symptoms measured by visual analogue scales (VAS) 
score between the two groups before intervention 
P 
Placebo Ginger 
Symptom 
mean ± SD mean ± SD 
0.173 51.48 ± 31.30 41.03 ± 27.70 Difficulty chewing 
0.816 48.02 ± 32.60 49.80 ± 26.40 Difficulty swallowing 
0.851 39.52 ± 23.85 40.75 ± 27.01 Speech difficulty 
0.104 37.27 ± 32.90 24.73 ± 25.80 Affecting taste ability 
0.461 22.89 ± 23.76 18.62 ± 21.02 Burning sensation in the mouth 
SD: Standard deviation 
 
 
 
Figure 2. This figure shows that xerostomia has 
improved in the ginger group (with significant 
and non-significant xerostomia), when compared 
to the placebo group 
VAS: Visual analogue scales 
 
The severity of major symptoms of 
xerostomia (difficulty with chewing, 
swallowing and speech, affecting taste 
ability, and burning sensation in the mouth) 
were compared between both groups and 
there was no significant difference. The 
findings indicated that both groups were the 
same before the intervention (Table 3). 
Patients were questioned about the effect of 
treatment on their quality of life and 
improvement of dry mouth symptoms on 
day 14 (end of intervention) (Table 1). The 
questions were yes/no type. The chi-square 
test showed that there was no significant 
differences between the two groups 
regarding improvement of dry mouth 
symptoms (including speech, chewing and 
deglutition difficulties and burning 
sensation) and quality of life issues such as 
dry mouth throughout the day, dry mouth 
throughout the night, awakening in the night 
due to dry mouth, affecting taste ability, 
decreased denture retention, meeting less 
people, speaking less to people, and going 
out less than before (Table 4). 
 
Table 4. The effect of treatment on improvement of dry mouth symptoms and quality of life 
P 
Placebo Ginger 
Response 
Item 
Total  
[n (%)] 
No  
[n (%)] 
Yes  
[n (%)] 
Total  
[n (%)] 
No  
[n (%)] 
Yes  
[n (%)] 
0.140 25 (100) 15 (60.0) 10 (40.0) 30 (100) 12 (40.0) 18 (60.0) Did the drug make chewing easier? 
0.237 25 (100) 14 (56.0) 11 (44.0) 30 (100) 12 (40.0) 18 (60.0) Did the drug make swallowing easier? 
0.218 25 (100) 15 (60.0) 10 (40.0) 30 (100) 13 (43.3) 17 (56.7) Did the drug make talking easier? 
0.176 25 (100) 22 (88.0) 3 (12.0) 30 (100) 22 (73.3) 8 (26.7) If you have a burning mouth, did the 
product improve the burning sensation? 
0.092 29 (100) 11 (37.9) 18 (62.1) 28 (100) 5 (17.9) 23 (82.1) Did the drug make your dry mouth better? 
0.482 26 (100) 14 (53.8) 12 (46.2) 25 (100) 11 (44.0) 14 (56.0) Did the drug most useful in the night? 
0.732 23 (100) 14 (60.9) 9 (39.1) 18 (100) 10 (55.6) 8 (44.4) Did the drug stop you waking in the night? 
0.210 10 (100) 5 (50.0) 5 (50.0) 9 (100) 7 (77.8) 2 (22.2) Did the drug improve your sensation of taste? 
0.586 13 (100) 8 (61.5) 5 (38.5) 14 (100) 10 (71.4) 4 (28.6) If you wear denture, did the drug help with 
the retention of the denture? 
0.883 14 (100) 9 (64.3) 5 (35.7) 13 (100) 8 (61.5) 5 (38.5) Did you meet people more than you used to? 
0.469 12 (40.0) 7 (58.3) 5 (41.7) 11 (44.0) 8 (72.7) 3 (27.3) Did you speak to people more than you 
used to? 
0.386 8 (61.5) 6 (75.0) 2 (25.0) 4 (28.6) 2 (50.0) 2 (50.0) Did you get out of the house more than you 
used to? 
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However, concerning one question  
(dry mouth throughout the day) 82% of 
patients in the ginger group and 62% of 
patients in the placebo group felt 
improvement and this difference was 
marginally significant (P < 0.100). 
Following drug consumption, some 
patients reported some side effects. In the 
ginger group, 1 patient had constipation,  
2 patients had vertigo, and 2 had dyspepsia. In 
the placebo group, 2 patients had headache 
and 2 patients had dyspepsia. Because the side 
effects were few, it was probable that other 
elements caused these problems, rather than 
ginger or placebo consumption. 
Before the study was done, patients 
inquired about the use of saliva substitute or 
other products to decrease dry mouth. No 
one reported using artificial saliva. Four 
patients (6.5%) were using BioXtra gel. These 
patients agreed to discontinue using BioXtra 
gel in order to join the study. 
Discussion 
Some researchers conducted on the ginger 
plant have indicated parasympathomimetic 
effect.13,17,28 In researches conducted by 
Ghayur and Gilani, ginger was shown to 
have spasmolytic effect through blocking 
calcium channels27 and was involved in 
activation of postsynaptic muscarinic M3 
receptors in the stomach of rats.17 Chamani  
et al. discovered that ginger derivate was 
effective in increasing saliva of rats.13 
The result of the recent study indicates 
that dry mouth improvement in patients who 
used ginger was marginally more significant 
than in patients in the placebo group. The 
statistical analysis showed that there was no 
significant difference in severity of symptoms 
of xerostomia between two groups and both 
groups of patients were similar in age, 
gender and time elapsed after last 
radiotherapy. This issue indicates that not 
only the two groups before the study were 
completely identical, but also it insists on the 
power of intervention and true randomly 
chosen sampling. 
In this study, the improvement of 
xerostomia after ginger usage was marginally 
significant (P = 0.057). To achieve the best 
reliable results, the patients were divided into 
two groups with significant and  
non-significant xerostomia. The improvement 
of dry mouth was assessed based on this 
categorization. If this division was not done 
and all of the patients who had significant 
and non-significant xerostomia in the ginger 
or placebo group were assessed together, the 
results of the comparison between control 
and study groups were completely 
significant by the t-test (P = 0.044). In this 
study focus was placed on the two-way 
ANOVA test, to attain the most reliable 
results (P = 0.057). 
Because the decrease in xerostomia 
through ginger usage was marginally 
significant as compared to the placebo, it is 
proposed that in future researches, more 
attention should be placed to increase sample 
size to gain the best absolute results. 
Despite the improvement of xerostomia 
there was no meaningful difference between 
two groups regarding improvement of dry 
mouth symptoms and quality of life issues on 
day 14. It is probable that non-significant 
results were related to the small sample size 
and the psychological effect of the placebo. 
It is not deniable that the range of 
radiation side effects depends on several 
factors such as scope, dose and volume of 
radiation actors rather than the ordinary 
performance of the salivary gland.29 By 
consulting the radiotherapist-oncologist, 
there was no chance to differentiate the 
patients based on these factors, so it is 
probable that such factors in small sample 
could have biased the research results. 
The radiotherapist-oncologist advised the 
patients to use water and liquids, to have 
good oral hygiene, and to use nystatin and 
chlorhexidine mouthwashes, and fluconazole 
during treatment. This advice about liquid 
consumption could have some effects on dry 
mouth. We had no remedy to omit this 
confounder factor, because it is necessary to 
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advise patients to use water and liquid based 
on moral rules. 
For evaluation of severity of xerostomia 
and the treatment effect, dry mouth scores 
derived from VAS were recorded on days 0 
and 14 in this study.  
The best treatment for decreased 
salivation is protection. Advances in 
technology in the field of therapeutic 
radiation spares a portion of the major 
salivary glands from destruction.7,12 Great 
efforts were also made to develop 
radioprotective medications to decrease side 
effects of radiotherapy. By systemic 
application of amifostine, salivary gland 
function could be improved after therapy.29 
One reliable alternative to treat 
radiotherapy-induced hyposalivation is stem 
cell replacement. The recent identiﬁcation of 
stem and progenitor cell populations will aid 
with future research, but a better 
understanding of cell turnover in salivary 
glands is still needed.30 
However, some patients who are going 
under radiotherapy are still suffering from 
the complications of xerostomia and more 
studies are needed to find new solutions for 
this problem.  
Limitations 
There was some limitation in our study such 
as different culture and language barrier 
(participants spoke Turkish, Kurdish, etc.) 
that made some difficulties in answering the 
examiner’s question, and low number of 
patients for treatment follow-up because of 
living distant from the institute which made 
sample size small to review. So, further 
studies in larger group of patients are 
recommended to provide the effect of ginger 
on various complaints of xerostomia. 
Conclusion 
This study showed that ginger decreased the 
severity of dry mouth in patients with post-
radiation xerostomia, but it did not improve 
dry mouth symptoms or patients’ quality of 
life. Conducting more research on this plant 
in the future, with attention to special 
characteristics (low cost, availability, safety) 
is advised. 
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